ArticleAnnals of the New York Academy of Sciences2014
Economic analysis of opportunities to accelerate Alzheimer's disease research and development.
Article in Annals of the New York Academy of Sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- From General-Purpose to Disease-Specific Features: Aligning LLM Embeddings on a Disease-Specific Biomedical Knowledge Graph for Drug Repurposing.bioRxiv : the preprint server for biology · 2026Article
- 4-Chlorobenzylamine Containing Maleic Acid Derivatives: Synthesis,ACS chemical neuroscience · 2026Article
- A human neuron alzheimer's disease model reveals barriers to senolytic translatability.Alzheimer's research & therapy · 2025Article
- AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer's Disease clinical trial.Nature communications · 2025Article
- Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson's Disease.Journal of movement disorders · 2025Article
- Standardized statistical framework for comparison of biomarkers: Techniques from ADNI.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Nanoscale flow cytometry-based quantification of blood-based extracellular vesicle biomarkers distinguishes MCI and Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Hepatotoxicity assessment of innovative nutritional supplements based on olive-oil formulations enriched with natural antioxidants.Frontiers in nutrition · 2024Article
- Accelerating Alzheimer's therapeutic development: The past and future of clinical trials.Cell · 2023Review
- Feasibility of common, enjoyable game play for assessing daily cognitive functioning in older adults.Frontiers in neurology · 2023Article
- Data sharing in neurodegenerative disease research: challenges and learnings from the innovative medicines initiative public-private partnership model.Frontiers in neurology · 2023Review
- Early termination of pivotal trials in Alzheimer's disease-Preserving optimal value for participants and science.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- The role of basket trials in drug development for neurodegenerative disorders.Alzheimer's research & therapy · 2022Review
- The costs of developing treatments for Alzheimer's disease: A retrospective exploration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Review
- Neurotechnological Approaches to the Diagnosis and Treatment of Alzheimer's Disease.Frontiers in neuroscience · 2022Review
- Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures.Journal of Alzheimer's disease : JAD · 2022Review
- Can FDA-Approved Immunomodulatory Drugs be Repurposed/Repositioned to Alleviate Chronic Pain?Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021Review
- Review
- Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer's disease.NPJ digital medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of disease-modifying treatments for Alzheimer's disease (AD) faces a number of barriers. Among these are the lack of surrogate biomarkers, the exceptional size and duration of clinical trials, difficulties in identifying appropriate populations for clinical trials, and the limitations of monotherapies in addressing such a complex multifactorial disease. This study sets out to first estimate the consequent impact on the expected cost of developing disease-modifying treatments for AD and then to estimate the potential benefits of bringing together industry, academic, and government stakeholders to co-invest in, for example, developing better biomarkers and cognitive assessment tools, building out advanced registries and clinical trial-readiness cohorts, and establishing clinical trial platforms to investigate combinations of candidate drugs and biomarkers from the portfolios of multiple companies. Estimates based on interviews with experts on AD research and development suggest that the cost of one new drug is now $5.7 billion (95% confidence interval (CI) $3.7-9.5 billion) and could be reduced to $2.0 billion (95% CI $1.5-2.9 billion). The associated acceleration in the arrival of disease-modifying treatments could reduce the number of case years of dementia by 7.0 million (95% CI 4.4-9.4 million) in the United States from 2025 through 2040.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.